VEGFA and glioblastoma: However, this trial of an endoglin inhibitor combined with a VEGF inhibitor in GBM was remarkable for the fact that both vascularly-active drugs could be administered at their recommended Phase II doses (10 mg/kg each) without the development of tumor hemorrhage.